Vaccines and immunotherapies against hepatitis B and hepatitis C viruses

Journal of Viral Hepatitis

Volumn 14, Issue SUPPL. 1, 2007, Pages 97-103

  Inchauspe G ^b   Michel, M L ^a,c  

^a INSTITUT PASTEUR   (France)

^b TRANSGENE S A   (France)

^c INSERM   (France)

Author keywords

Chronic hepatitis; Hepatitis B virus; Hepatitis C virus; Immunotherapy; Vaccine

Indexed keywords

ANA 975; CPG 10101; DNA VACCINE; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS C VACCINE; IMMUNOLOGICAL ADJUVANT; ISATORIBINE; LAMIVUDINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; UNCLASSIFIED DRUG; VACCINIA VACCINE;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; HEPACIVIRUS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; VIRAL HEPATITIS VACCINES;

EID: 35448967046     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2007.00922.x     Document Type: Conference Paper

References (53)

1. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995 13: 29 60.
2. Bertoni R, Sidney J, Fowler P, Chesnut RW, Chisari FV, Sette A. Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis. J Clin Invest 1997 100 (3 503 513.
3. Maini MK, Boni C, Ogg GS et al. Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology 1999 117 (6 1386 1396.
4. Rehermann B, Fowler P, Sidney J et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995 181 (3 1047 1058.
5. Jung MC, Diepolder HM, Spengler U et al. Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection. J Virol 1995 69 (6 3358 3368.
6. Ferrari C, Bertoletti A, Penna A et al. Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest 1991 88 (1 214 222.
7. Mizukoshi E, Sidney J, Livingston B et al. Cellular immune responses to the hepatitis B virus polymerase. J Immunol 2004 173 (9 5863 5871.
8. Bertoletti A, Maini MK. Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection?. Curr Opin Microbiol 2000 3 (4 387 392.
9. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005 5 (3 215 229.
10. Webster GJ, Reignat S, Brown D et al. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 2004 78 (11 5707 5719.
11. Franzese O, Kennedy PT, Gehring AJ et al. Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection. J Virol 2005 79 (6 3322 3328.
12. Xu D, Fu J, Jin L et al. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006 177 (1 739 747.
13. Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 1997 25 (2 449 458.
14. Wedemeyer H, He XS, Nascimbeni M et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 2002 169 (6 3447 3458.
15. Chang KM, Thimme R, Melpolder JJ et al. Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. Hepatology 2001 33 (1 267 276.
16. Lechner F, Gruener NH, Urbani S et al. CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur J Immunol 2000 30 (9 2479 2487.
17. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001 194 (10 1395 1406.
18. Diepolder HM, Gerlach JT, Zachoval R et al. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 1997 71 (8 6011 6019.
19. Rosen HR, Miner C, Sasaki AW et al. Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages. Hepatology 2002 35 (1 190 198.
20. Vertuani S, Bazzaro M, Gualandi G et al. Effect of interferon-alpha therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals. Eur J Immunol 2002 32 (1 144 154.
21. Wertheimer AM, Miner C, Lewinsohn DM, Sasaki AW, Kaufman E, Rosen HR. Novel CD4+ and CD8+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection. Hepatology 2003 37 (3 577 589.
22. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003 197 (5 633 642.
23. Wakita T, Pietschmann T, Kato T et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005 11 (7 791 796.
24. Bartosch B, Bukh J, Meunier JC et al. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A 2003 100 (24 14199 14204.
25. Logvinoff C, Major ME, Oldach D et al. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A 2004 101 (27 10149 10154.
26. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005 436 (7053 946 952.
27. Urbani S, Amadei B, Tola D et al. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol 2006 80 (22 11398 11403.
28. Boni C, Penna A, Bertoletti A et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 2003 39 (4 595 605.
29. Boni C, Penna A, Ogg GS et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001 33 (4 963 971.
30. Michel ML, Mancini-Bourgine M. Therapeutic vaccination against chronic hepatitis B virus infection. J Clin Virol 2005 34 (Suppl. 1 S108 S114.
31. Wen YM, Wu XH, Hu DC, Zhang QP, Guo SQ. Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy. [Letter]. Lancet 1995 345 (8964 1575 1576.
32. Isvhld2006. Abstracts of the 12th international symposium on viral hepatitis and liver disease. J Clin Virol 2006 36 S2(Suppl. 2): S4 S32.
33. Lobaina Y, Palenzuela D, Pichardo D, Muzio V, Guillen G, Aguilar JC. Immunological characterization of two hepatitis B core antigen variants and their immunoenhancing effect on co-delivered hepatitis B surface antigen. Mol Immunol 2005 42 (3 289 294.
34. Betancourt AA, Delgado CA, Estevez ZC et al. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens. Int J Infect Dis 2007 11: 394 401.
35. Roy MJ, Wu MS, Barr LJ et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 2001 19 (7-8 764 778.
36. Rottinghaus ST, Poland GA, Jacobson RM, Barr LJ, Roy MJ. Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination. Vaccine 2003 21 (31 4604 4608.
37. Mancini-Bourgine M, Fontaine H, Scott-Algara D, Pol S, Brechot C, Michel ML. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 2004 40 (4 874 882.
38. Yang SH, Lee CG, Park SH et al. Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Gene Ther 2006 13: 1110 1117.
39. Vitiello A, Ishioka G, Grey HM et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 1995 95 (1 341 349.
40. Livingston BD, Alexander J, Crimi C et al. Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans. J Immunol 1999 162 (5 3088 3095.
41. Wang J, Gujar SA, Cova L, Michalak TI. Bicistronic woodchuck hepatitis virus core and gamma interferon DNA vaccine can protect from hepatitis but does not elicit sterilizing antiviral immunity. J Virol 2007 81: 903 916.
42. Lindenbach BD, Evans MJ, Syder AJ et al. Complete replication of hepatitis C virus in cell culture. Science 2005 309 (5734 623 626.
43. Bukh J. A critical role for the chimpanzee model in the study of hepatitis C. Hepatology 2004 39 (6 1469 1475.
44. Arribillaga L, Sarobe P, Arina A et al. Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus. Vaccine 2005 23 (27 3493 3499.
45. Engler OB, Schwendener RA, Dai WJ et al. A liposomal peptide vaccine inducing CD8+ T cells in HLA-A2.1 transgenic mice, which recognise human cells encoding hepatitis C virus (HCV) proteins. Vaccine 2004 23 (1 58 68.
46. Simon BE, Cornell KA, Clark TR, Chou S, Rosen HR, Barry RA. DNA vaccination protects mice against challenge with Listeria monocytogenes expressing the hepatitis C virus NS3 protein. Infect Immun 2003 71 (11 6372 6380.
47. Encke J, zu Putlitz J, Geissler M, Wands JR. Genetic immunization generates cellular and humoral immune responses against the nonstructural proteins of the hepatitis C virus in a murine model. J Immunol 1998 161 (9 4917 4923.
48. Choo QL, Kuo G, Ralston R et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A 1994 91 (4 1294 1298.
49. Rosa D, Campagnoli S, Moretto C et al. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci U S A 1996 93 (5 1759 1763.
50. Nevens F, Roskams T, Van Vlierberghe H et al. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 2003 38 (5 1289 1296.
51. Folgori A, Capone S, Ruggeri L et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 2006 12 (2 190 197.
52. Weeratna RD, Makinen SR, McCluskie MJ, Davis HL. TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). Vaccine 2005 23 (45 5263 5270.
53. Horsmans Y, Berg T, Desager JP et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 2005 42 (3 724 731.